Amid a swell of regulatory successes in the myasthenia gravis arena this decade, Amgen is wading into the fray with a new ...

Generalized myasthenia gravis is Uplizna’s second new indication this year, after the FDA cleared the anti-CD19 antibody for ...

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen Inc. has initiated a Phase 3 clinical trial titled A Phase 3 ...

After three decades spent rising through the ranks of sales and marketing teams at major pharmas, Chris Boulton is taking the ...

Drug development in biotechnology takes time. A lot of time. On average, it takes 10 to 15 years to take a medicine from ...

HSBC raised the firm’s price target on Amgen (AMGN) to $425 from $381 and keeps a Buy rating on the shares as part of a 2026 ...

Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming ...

FDA Approves Treatment for gMG FDA Approves Amgen’s UPLIZNA® (inebilizumab-cdon) for Generalized Myasthenia Gravis (gMG), ...

Curious if Amgen is worth your investment dollars right now? Let’s take a clear-eyed look at where the stock stands and whether the value justifies the price. Amgen's stock has been on a strong upward ...

The FDA’s approval of Uplizna for antibody-positive generalized myasthenia gravis introduces a twice-yearly CD19-targeted therapy option for the rare autoimmune condition. The FDA has approved Amgen’s ...

According to Benzinga Pro, Amgen Inc's peer group average for short interest as a percentage of float is 6.86%, which means ...

The Muscular Dystrophy Association (MDA) recognizes the U.S. Food and Drug Administration (FDA) approval of Amgen's UPLIZNA(R) (inebilizumab-cdon) for the treatment of generalized myasthenia gravis ...